Send to

Choose Destination
Cancer Cell Int. 2019 Jan 3;19:2. doi: 10.1186/s12935-018-0720-y. eCollection 2019.

T cell receptor-engineered T cells for leukemia immunotherapy.

Zhang Y1,2, Li Y1,2.

Author information

1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, Guangzhou, 510632 People's Republic of China.
2Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632 China.


At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy is an effective option for leukemia therapy. Recently, T cell immunotherapy studies have mainly focused on chimeric antigen receptor- and T cell receptor-engineered T cells. Clinical trials involving chimeric antigen receptor-engineered T cells have been a major breakthrough and became a novel therapy for leukemia. As another potential therapy for leukemia, clinical application of TCR-engineered T cells remains in its infancy. This article presents a review of the current status of anti-leukemia immunotherapy using leukemia antigen-specific TCR-engineered T cells.


Immunotherapy; Leukemia; T cell receptor-engineered T cells

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center